Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors
Authors
Keywords
Tumor Microenvironment, Acidity, mTORC1, Rapamycin, Sodium Bicarbonate, Resistance Mechanisms
Journal
Molecular Cancer
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-12-05
DOI
10.1186/s12943-016-0562-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy
- (2015) Shari Pilon-Thomas et al. CANCER RESEARCH
- Acidosis promotes invasiveness of breast cancer cells through ROS-AKT-NF-κB pathway
- (2015) Subash C. Gupta et al. Oncotarget
- Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
- (2014) Oscar R. Colegio et al. NATURE
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- Acidity Generated by the Tumor Microenvironment Drives Local Invasion
- (2013) V. Estrella et al. CANCER RESEARCH
- Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis
- (2013) Pengda Liu et al. NATURE CELL BIOLOGY
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes
- (2012) A. Calcinotto et al. CANCER RESEARCH
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Systemic Buffers Inhibit Carcinogenesis in TRAMP Mice
- (2012) Arig Ibrahim-Hashim et al. JOURNAL OF UROLOGY
- Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment
- (2011) Jonathan W. Wojtkowiak et al. MOLECULAR PHARMACEUTICS
- Interfering with pH regulation in tumours as a therapeutic strategy
- (2011) Dario Neri et al. NATURE REVIEWS DRUG DISCOVERY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of mTORC1 Signaling by pH
- (2011) Aruna D. Balgi et al. PLoS One
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer
- (2010) Johanna Chiche et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Bicarbonate Increases Tumor pH and Inhibits Spontaneous Metastases
- (2009) I. F. Robey et al. CANCER RESEARCH
- The Potential Role of Systemic Buffers in Reducing Intratumoral Extracellular pH and Acid-Mediated Invasion
- (2009) A. S. Silva et al. CANCER RESEARCH
- mTOR and cancer: many loops in one pathway
- (2009) Alejo Efeyan et al. CURRENT OPINION IN CELL BIOLOGY
- pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity
- (2009) Angelo De Milito et al. INTERNATIONAL JOURNAL OF CANCER
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- (2009) M. G. Vander Heiden et al. SCIENCE
- The Pharmacology of mTOR Inhibition
- (2009) D. A. Guertin et al. Science Signaling
- Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis through the Regulation of the Intracellular pH
- (2008) J. Chiche et al. CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More